Looking at the universe of stocks we cover at Dividend Channel, on May 28, First Financial Bancorp�(FFBC), Goldman Sachs�(GS) and M & T Bank Corp.�(MTB) will all trade ex-dividend for their respective upcoming dividends. First Financial Bancorp will pay its quarterly dividend of $0.15 on July 1, Goldman Sachs will pay its quarterly dividend of $0.55 on June 27 and M & T Bank�will pay its quarterly dividend of $0.70 on June 30.
START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen 禄
As a percentage of FFBC’s recent stock price of $16.29, this dividend works out to approximately 0.92%, so look for shares of First Financial Bancorp to trade 0.92% lower — all else being equal — when FFBC shares open for trading on Wednesday. Similarly, investors should look for GS to open 0.34% lower in price and for MTB to open 0.58% lower, all else being equal.
Top 5 High Tech Stocks To Own For 2015: Perrigo Company PLC (PRGO)
Perrigo Company plc, incorporated on March 23, 1988, is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri. The Company�� businesses include Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, Life Sciences and Other Businesses. The Company offers Healthcare Products across a range of product categories primarily in the United States, the United Kingdom, Mexico, Israel and Australia, and distributes into dozens of other markets worldwide, including Canada, China and Latin America. In February 2014, the Company announced that it has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc.
The Company operates through several wholly owned subsidiaries. In the United States, its operations are conducted primarily through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., PBM Products, LLC, PBM Nutritionals, LLC, Paddock Laboratories, LLC, Perrigo Diabetes Care, LLC (formerly CanAm Care, LLC), Sergeant's Pet Care Products, Inc. and Fidopharm, Inc. Outside the United States, its operations are conducted primarily through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Galpharm Healthcare Ltd., Orion Laboratories Pty Ltd and Rosemont Pharmaceuticals Ltd.
Consumer Healthcare
Perrigo Consumer Healthcare (CHC) operation includes the Company's United States, United Kingdom and Mexico manufacturing operations supporting the sale of OTC pharmaceutical products. Perrigo CHC supplies more than 15 categories and 500 formulas and offers analgesics, cough and cold remedies, and gastrointestinal and feminine hygiene products, as w! ell as vitamins, dietary supplements and nutritional drinks. Perrigo offers a range of products, such advertised brand products as Tylenol, Advil or One-A-Day. Tylenol has acetaminophen as an active ingredient and is available in stores' analgesic (pain reliever) aisle. Store-brand acetaminophen is located next to the national brand, offering the same active ingredient (acetaminophen) and the same pain relief.
Perrigo Nutritionals
Perrigo is a manufacturer of nutrition products for the store brand market. Nutrition products include infant formula, pediatric nutritionals and vitamins, minerals, and supplements. Acquired by Perrigo, Perrigo Nutritionals, formerly PBM Products, LLC, had introduced private-label, or store-brand infant formulas to the United States. Perrigo Nutritionals is the supplier of store-brand infant formulas and nutrition products. With distribution to major retailers, Perrigo Nutritional products can be found in more than 40,000 retail locations around the world. Its pediatric nutritionals business extends its offerings to children well beyond infancy. Its baby cereals, toddler foods, and pediatric nutritional drinks are available as store brands at various retail locations throughout the United States and the international community. Perrigo manufactures a range of vitamins, minerals, and supplements, in every major segment of the business. Marketed under the store brand labels of the retailers in the food, drug, mass-merchandise and wholesale club channels, it manufactures over 395 formulas of dietary supplements. Its brands include Centrum, One-A-Day, Flintstones, and Osteo-Bi-Flex.
Rx Pharmaceuticals
The Company�� Rx Pharmaceuticals business is focused on the development, manufacture and sale of generic prescription drug products, primarily for the United States market. Manufacturing operations are based in the United States and Israel. Perrigo's portfolio focuses on complex, high-barrier ophthalmological, topical foam and or! al liquid! formulations. Its products include Acetylcysteine Injection 200 mg/mL (6g/30mL), Acetylcysteine Injection 6 g/30 mL (200 mg/1 mL), NOVAPLUS, ACTIDOSE with SORBITOL, ACTIDOSE-AQUA, ASPIRIN SUPPOSITORIES USP, Bacitracin Ophthalmic Ointment USP, Belladonna and Opium Suppositories C-II, BENZOIN COMPOUND TINCTURE USP, Benzoyl Peroxide 10% Acne Medication Wash, CLOBETASOL PROPIONATE LOTION 0.05% and Docusate Sodium.
Active Pharmaceutical Ingredients
Primarily through the Company�� Israel-based business, Perrigo develops, manufactures and markets the complex chemicals and active pharmaceutical ingredients used worldwide by the generic drug industry. Certain of these ingredients are also used in Perrigo's own pharmaceutical products. It manufactures API at facilities in Israel, India and China. Perrigo API specializes in tailor-made research and process development of APIs and Finished Dosage Forms (FDFs).
Life Sciences
Through the Company�� Israel-based business, Perrigo markets and manufactures branded prescription drugs and medical diagnostic products through exclusive agreements with pharmaceutical companies. Its Pharmaceutical and Medical Diagnostic Products businesses also market and manufacture branded prescription drugs under licenses. Other pharmaceutical and medical diagnostics products are imported to Israel through exclusive agreements. Products in life sciences segment include TYSABRI and ELND005. TYSABRI (natalizumab) is indicated for treatment of: Multiple Sclerosis: as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. TYSABRI is recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate MS therapy; Crohn�� Disease (CD): Inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn�� disease with e! vidence o! f inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of tumor necrosis factor-伪.
Other
Perrigo's Pharmaceutical and Medical Diagnostic Products business markets and manufactures branded prescription drugs under licenses. Other pharmaceutical and medical diagnostic products are imported to Israel through exclusive agreements with pharmaceutical and diagnostics companies. This business is divided into two departments: Pharma-Israel and Tayco Diagnostics. Pharma-Israel operates in the Israeli market as a partner in the marketing, sales and distribution of Rx (dermatology, gastroenterology, blood products, CNS, urology and other fields), OTC, generics, branded generics, dermo-cosmetics and dietary supplements. Tayco, the diagnostics division of Perrigo-Israel Pharmaceuticals Ltd., specializes in marketing and sales of medical laboratory systems, reagents, accessories and consumables. It also markets self-monitoring medical devices for diagnosis and treatment of diabetes. The division operates throughout Israel to service the central laboratory, hospital, clinic, point of care and self-testing markets. Its activities in the medical and research fields in Israel cover all market segments: medical (private and public health services), research institutions and the biotech industry.
The Company competes with Dr. Reddy�� Laboratories, Ltd., Actavis Inc., Aaron Industries, Inc., Ohm Laboratories, Inc., PL Developments, LNK International, Inc., Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber), Danone Baby Nutrition, Bayer AG, Pfizer, Inc., Rexall Sundown, Inc., Apotex, Glenmark Generics Inc., Impax, Prasco, Sandoz, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, and Zydus Pharmaceuticals.
Advisors' Opinion:- [By Rich Duprey]
Investors going with health-care products maker Perrigo� (NYSE: PRGO ) �will receive a�quarterly cash dividend�of�$0.09 per share on June 18 to shareholders of record at the close of business on May 31 for the fiscal third quarter of 2013.
- [By Laura Brodbeck]
Stocks moving in the Premarket included:
Boeing(NYSE: BA) lost 1.98 percent in premarket trade after falling 0.25 percent on Friday. Alcoa(NYSE: AA) fell 1.32 percent in premarket trade after gaining 3.58 percent last week. Perrigo Company PLC (NYSE: PRGO) gained 0.36 percent in premarket trade after rising 0.36 percent on Friday. Berkshire HathawayInc (NASDAQ: BRKB) gained 0.27 percent in premarket trade after increasing 5.95 percent last week.Earnings
- [By Ben Levisohn]
While the Paladin deal expands potential growth areas for the company, Endo�� business development focus remains on the heavily fragmented US market, where the company believes it can create the most value by operating acquired assets more efficiently. Management sees a robust pipeline of potential future deals and does not necessarily view other companies that benefit from a low tax rate [(Actavis (ACT), Perrigo (PRGO), Valeant Pharmaceuticals International (VRX))] as direct competitors for the assets it is targeting. We believe business development is likely to accelerate post the Paladin deal and the re-domicile to Ireland, and view Endo as in the early stages of its consolidation strategy…And with greater than $2 billion in capacity to do deals, we expect business development to accelerate.
- [By Meg Tirrell]
There have been 44 acquisitions of specialty drug companies for more than $500 million in the last three years, according to data compiled by Bloomberg. The average disclosed size was $1.2 billion and average premium was 20 percent, the data show. The largest deal was Perrigo Co. (PRGO)�� purchase of Elan Corp. for $6.2 billion earlier this year.
Top Up And Coming Stocks To Watch For 2014: CNOOC Limited(CEO)
CNOOC Limited, through its subsidiaries, engages in the exploration, development, production, and sale of crude oil, natural gas, and other petroleum products. The company?s oil and natural gas properties are located in offshore China, which include Bohai Bay, western south China Sea, eastern south China Sea, and east China Sea, as well as in Indonesia, Iraq, and other regions in Asia; and Oceania, Africa, North America, and South America. As of December 31, 2010, the company had net proved reserves of approximately 2.99 billion barrels-of-oil equivalent, including approximately 1.92 billion barrels of crude oil and 6,458.3 billion cubic feet of natural gas. It also provides bond issuance services; and has a joint venture with Bridas Energy Holdings. CNOOC Limited was founded in 1982. The company is headquartered in Central, Hong Kong, and is considered a Red Chip company due to its listing on the Hong Kong Stock Exchange. CNOOC Limited is a subsidiary of China National Of fshore Oil Corporation.
Advisors' Opinion:- [By Paul Ausick]
No corporate merger valued at more than $5 billion occurred in 2013, while there were several deals valued at more than $10 billion in 2012. Two of 2012�� biggest deals were Freeport-McMoRan Copper and Gold Inc.�� (NYSE: FCX) acquisition of McMoRan Exploration and Plains Exploration & Production for a total of about $20 billion. Another big acquisition in 2012 was Cnooc Ltd.�� (NYSE: CEO) $15 billion deal for Nexen Energy.
- [By Arjun Sreekumar]
For instance, Chesapeake's 2010 agreement with China's largest energy company, CNOOC (NYSE: CEO ) , allowed CNOOC to purchase one-third undivided interest in a portion of Chesapeake's Eagle Ford assets in exchange for financing 75% of Chesapeake's drilling and completion expenses.
Top Up And Coming Stocks To Watch For 2014: Dephasium Corp (DPHS)
Dephasium Corp., formerly Pay Mobile, Inc., incorporated on November 17, 2005, is a development-stage company. As of December 31, 2012, the Company was seeking new business opportunities. On June 3, 2013, Dephasium Corp announced that it has completed the acquisition of the ANCILIA from Dephasium Ltd.
The Company was engaged in the business of providing integrated payment solutions for consumers and corporate clients by incorporating its mobile payment technology with the issuance of open-loop prepaid Visa and MasterCard cards. As of December 31, 2012, the Company had no operations.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks BluForest Inc (OTCMKTS: BLUF), Dephasium Corp (OTCMKTS: DPHS) and IceWEB, Inc (OTCBB: IWEB) have been getting some attention for at least a few weeks now thanks to paid for promotional activity. Of course, there is nothing wrong with properly disclosed stock promotions, but one of these stocks also has a former shareholder who has filed a civil action against it alleging there is an illegal ��ump and dump��scheme going on. So what�� the whole story and more importantly, what will happen with these small cap stocks when the well from promoters eventually goes dry? Here is a closer look and a quick reality check:
Top Up And Coming Stocks To Watch For 2014: Xoom Corp (XOOM)
Xoom Corporation (Xoom), incorporated on October 10, 2012, is engaged in online international money transfer service. Its customers use Xoom to send money to family and friends in 30 countries. The Company generates revenue from transaction fees charged to customers and from foreign exchange spreads on transactions where the payout currency is other than United States dollars. In February 2014, Xoom Corp acquired BlueKite, LTD, a technology company that develops solutions and applications.
The Company�� solutions are designed to offer customers a convenient, fast and cost-effective way to send money to family and friends at any time, from any Internet-enabled location. The Company�� solutions include Origination, Funding, Disbursement and Transaction Processing.
Advisors' Opinion:- [By John Udovich]
Small cap money transfer stock Euronet Worldwide, Inc (NASDAQ: EEFT) and Wal-Mart Stores, Inc (NYSE: WMT) have announced an exclusive money transfer service called "Walmart-2-Walmart,��meaning its time to take a closer look at the stock along with the performance of peers like Moneygram International Inc (NASDAQ: MGI), Xoom Corp (NASDAQ: XOOM) and The Western Union Company (NYSE: WU) which fell 17.68%, 4.32% and 4.98%, respectively.
- [By Jake L'Ecuyer]
Equities Trading UP
Xoom (NASDAQ: XOOM) shares shot up 15.58 percent to $22.77 after the company reported upbeat Q1 results and issued a strong FY14 outlook. - [By Alex Planes]
What: Shares of Xoom (NASDAQ: XOOM ) have rocketed higher today and are now sitting 15% above yesterday's close after obliterating analyst estimates with strong earnings.
- [By Jake L'Ecuyer]
Equities Trading UP
Xoom (NASDAQ: XOOM) shares shot up 21.68 percent to $23.97 after the company reported upbeat Q1 results and issued a strong FY14 outlook.
Top Up And Coming Stocks To Watch For 2014: Nicholas Financial Inc.(NICK)
Nicholas Financial, Inc., through its subsidiaries, operates as a specialized consumer finance company. The company engages in acquiring and servicing contracts for purchases of new and used automobiles and light trucks. It also makes direct loans and sells consumer-finance related products. In addition, the company engages in developing, marketing, supporting, and updating industry-specific computer application software for small businesses located primarily in the Southeast United States. As of April 5, 2011, it operated 56 branch locations in 14 Southeastern and Midwestern states. The company was founded in 1986 and is headquartered in Clearwater, Florida.
Advisors' Opinion:- [By Lauren Pollock]
Prospect Capital Corp.(PSEC) said it agreed to buy Nicholas Financial Inc.(NICK) in a stock deal valued at about $199 million that the investment firm expects will expand its presence in the car-loan industry. Prospect Capital is offering $16 a share for Nicholas, a 4.5% premium over Tuesday’s closing price. Nicholas Financial shares edged up 2.8% to $15.70 premarket.
No comments:
Post a Comment